Skip to main content
SpringerLink
Log in

Fidarestat

Aldos, SK 860, SNK 860

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Mealy N, Castañer J. SNK-860: symptomatic antidiabetic, aldose reductase inhibitor. Drugs of the Future 21: 261–265, Mar 1996

    CAS  Google Scholar 

  2. Yamaguchi T, Miura K, Usui T, et al. Synthesis and aldose reductase inhibitory activity of 2-substituted-6-fluoro-2,3-dihydrospiro [4H-1-benzopyran-4,4′-imidazolidine]-2′,5′-diones. Arzneimittel-Forschung/Drug Research 44: 344–348, Mar 1994

    CAS  Google Scholar 

  3. Mizuno K, Kato N, Matsubara A, et al. Effects of a new aldose reductase inhibitor, (2S, 4S)-6- fluoro-2′,5′-dioxospiro[chroman-4,4′-imidazolidine]-2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocininduced diabetic rats. Metabolism- Clinical and Experimental 41: 1081–1086, Oct 1992

    Article  PubMed  CAS  Google Scholar 

  4. Kato N, Mizuno K, Matsubara A, Nakano K, Kurono M, et al. Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2′,5′-dioxospiro-[chroman-4, 4′-imidazolidine]-2-carboxamide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats. Journal of Diabetes and its Complications 8: 27–32, Jan–Mar 1994

    Article  PubMed  CAS  Google Scholar 

  5. Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 24: 1776–1782, Oct 2001

    Article  PubMed  CAS  Google Scholar 

  6. Akita M, Mizuno K, Matsubara A, Nakano K, Kurono M. Effects of an aldose reductase inhibitor, SNK-860, on the histopathological changes of retinal tissues in a streptozotocininduced diabetic rat model. Acta Medica Okayama 47: 299–304, Oct 1993

    PubMed  CAS  Google Scholar 

  7. Mizuno K, Kato N, Makino M, et al. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy. Journal of Diabetes and its Complications 13: 141–150, May–Jun 1999

    Article  PubMed  CAS  Google Scholar 

  8. Asano T, Saito Y, Kawakami M, Yamada N. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. Journal of Diabetes and its Complications 16: 133–138, Mar–Apr 2002

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fidarestat. Drugs R&D 3, 232–234 (2002). https://doi.org/10.2165/00126839-200203040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200203040-00002

Keywords

Search

Navigation